Lantheus Medical Imaging
Trial Pipeline
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
NCT07357519
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
NCT06074510
DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
NCT03571672
DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function
NCT00401687
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What the Pipeline for Lantheus Medical Imaging Shows
According to the ClinicalTrials.gov registry, Lantheus Medical Imaging is linked to 32 US clinical trials across every stage of research activity. Of those, 29 studies are currently recruiting — about 91% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 6% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Lantheus Medical Imaging reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 29 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Lantheus Medical Imaging is Relapsed / Refractory Osteosarcoma with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.